Clinical Trial

A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 12, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to clarify the safety and efficacy of DEB-TACE combined with SALOX-HAIC in the treatment of unresectable advanced primary liver cancer. To determine whether this therapy can prolong the indicators such as PFS, TTP, OS, ORR, and DOR.
Trial Details
NCT Number NCT06823050
Lead Sponsor Xuhua Duan
Conditions Hepatocellular Carcinoma
Enrollment 59 participants
Start Date 2025-03-01
Primary Completion 2026-03-01 (estimated)
Study Completion 2028-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-02-12